AVISCERA bioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
Clusterin(Soluble) ELISA Kit

Alternative name:

  • Aging-associated gene 4 protein
  • Apolipoprotein J
  • Complement-associated protein SP-40,40
  • Testosterone-repressed prostate message 2

Plasma protein characteristics of long-term hemodialysis survivors

Hemodialysis (HD) patients are under recurrent circulatory stress, and hemodialysis has a high mortality rate. The characteristics of plasma proteomes in patients surviving long-term HD remain obscure, as well as the potential biomarkers in predicting prognoses. This study reports the proteome analyses of patient plasma from non-diabetic long-term HD (LHD, dialysis vintage 14.9±4.1 years, n = 6) and the age/sex/uremic etiology-comparable short-term HD (SHD, dialysis vintage 5.3±2.9 years, n = 6) using 2-DE and mass spectrometry. In addition, a 4-year longitudinal follow-up of 60 non-diabetic HD patients was subsequently conducted to analyze the baseline plasma proteins by ELISA in predicting prognosis. Compared to the SHD, the LHD survivors had increased plasma vitamin D binding proteins (DBP) and decreased clusterin, apolipoprotein A-IV, haptoglobin, hemopexin, complement factors B and H, and altered isoforms of α1-antitrypsin and fibrinogen gamma. During the 45.7±15 months for follow-up of the 60 HD patient cases, 16 patients died. Kaplan-Meier analysis demonstrated that HD patients with the lowest tertile of the baseline plasma DBP level have a significantly higher mortality rate. Multivariate Cox regression analysis further indicated that DBP is an independent predictor of mortality. In summary, the altered plasma proteins in LHD implicated accelerated atherosclerosis, defective antioxidative activity, increased inflammation/infection, and organ dysfunction. Furthermore, lower baseline plasma DBP in HD patients is related to mortality. The results suggest that the proteomic approach could help discover the potential biomarker in HD prognoses.
Lin YP, et al. PLoS One. 2012;7(7):e40232. Epub 2012 Jul 6.

Clusterin is a potential serum marker of hepatic carcinoma

To determine the differentially expressed serum proteins in patients with hepatoma carcinoma and identify a putative diagnostic marker. The isobaric tags for relative and absolute quantitation (iTRAQ) labeling method and LC-MALDI-TOF/TOF MS detection method were used to quantify serum proteins in hepatocellular carcinoma patients (n =20) and healthy individuals (n =20). Real-time reverse transcription-polymerase chain reaction was used to verify the differentially expressed proteins by analyzing the corresponding mRNA expression levels in the hepatic carcinoma and healthy hepatocyte samples, as well as in 30 pairs of patient-matched hepatic carcinoma and adjacent normal tissue samples. Western blot analysis was used to verify the protein expression in hepatic carcinoma cells. Fifty-one proteins were significantly differentially expressed between the hepatic carcinoma group and healthy controls. The iTRAQ protein profile showed that the serum level of clusterin was significantly lower in hepatoma carcinoma patients. The mRNA level of clusterin was 20-fold lower in hepatic carcinoma cells than in healthy hepatocytes, and was 2.38-fold lower in hepatoma tissues than that in adjacent normal tissues. The clusterin protein levels were significantly lower in hepatic carcinoma cells (8.06 vs normal hepatocytes: 27.81; P less than 0.01). The serum expresion of clusterin is significantly decreased in both serum and tissues of hepatic carcinoma patients. The relationship between hepatic carcinoma and clusterin should be evaluated in future studies.
Li Y, et al. Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):275-9. doi: 10.3760/cma.j.issn.1007-3418.2012.04.010.

Diabetes-Induced Renal Injury in Rats is Attenuated by Suramin

Progression of hyperglycemia-induced renal injury is a contributing factor for diabetic nephropathy (DN)-induced end stage renal disease (ESRD) and development of novel therapeutic strategies that act early to prevent progression of DN and ESRD are important. We examined the efficacy and mechanism(s) of suramin on hyperglycemia-induced renal injury before development of overt histological damage. Two groups of male Sprague Dawley rats received streptozotocin (STZ) and one group, saline. Three weeks later one STZ group received suramin (10 mg/kg). All animals were euthanized one week later (4 weeks). While there was a decrease in creatinine clearance between controls and STZ ± suramin rats, there was no difference in creatinine clearance between STZ rats ± suramin intervention. LC-MS/MS-based analysis revealed increases in urinary proteins that are early indicators of DN (e.g. cystatin C, clusterin, cathepsin B, retinol binding protein 4 and peroxiredoxin-1), in the STZ group and were blocked by suramin. Endothelial intracellular adhesion molecule-1 (ICAM-1) activation, leukocyte infiltration and inflammation; transforming growth factor-β1 (TGF-β1) signaling; TGF-β1/SMAD-3-activated fibrogenic markers fibronectin-1, alpha-smooth muscle actin (α-SMA) and collagenase 1A2 (COL1A2); activation of pro-inflammatory and pro-fibrotic transcription factors nuclear factor κB (NF-κB) and signal transducer and activator of transcription factor-3 (STAT-3), respectively, were all increased in STZ rats and suramin blocked these changes. In conclusion, delayed administration of suramin attenuated 1) urinary markers of DN, 2) inflammation by blocking NF-κB activation and ICAM-1-mediated leukocyte infiltration and 3) fibrosis by blocking STAT-3 and TGF-β1/Smad-3 signaling. These results support the potential use of suramin in DN.
Korrapati MC, et al. J Pharmacol Exp Ther. 2012 Jun 26. [Epub ahead of print]
 
mouse clusterin elisa kit was used to measure mouse serum samples
mouse rat soluble clusterin elisa kit sk00709-03 from aviscera bioscience Mouse/Rat Soluble Clusterin ELISA
Code No.: SK00709-03
Size: 96 T
Price: $360.00 USD
Standard Range:2.5-160 ng/ml
Sensitivity: 400 pg/ml
Sample Type: serum, EDTA plasma
Dilution factor:100-200
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF

 

Name
Code No.
Size
Price ($)
Mouse/Rat Soluble Clusterin ELISA Kit SK00709-03 96 T 360.00
Human Clusterin Rec (human cell derived) 00709-06-10 10 ug 160.00
Mouse Clusterin Rec (human cell derived) 00709-03-10 10 ug 160.00
Rabbit Anti Human Clusterin IgG A00709-06-100 100 ug 350.00
Rabbit Anti Mouse Clusterin IgG A00709-03-100 100 ug 350.00